Topotecan hydrochloride is under clinical development by Fujifilm and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Topotecan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Topotecan hydrochloride overview

Topotecan hydrochloride (FF-10850) is under development for the treatment of relapsed/refractory solid tumors like cervical cancer, sarcoma, neuroendocrine tumors, small cell lung cancer, Merkel cell carcinoma and ovarian cancer. It is a liposomal formulation which is developed based on nanodispersion technology. It is administered through intravenous route. It acts by targeting DNA topoisomerase I.

It was also under development for the treatment of colorectal cancer.

Fujifilm overview

Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, and imaging systems. The company offers document solutions such as office products, office printers, and allied production services and global services. Its major products include color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. It has business presence across the Americas, Europe, Africa, Oceanic and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.

For a complete picture of Topotecan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.